Navigation Links
Beware: Newly recognized heart cardiomyopathy is not always benign
Date:3/9/2013

Even though a newly recognized cardiomyopathy, which mainly impacts women, is typically treatable, Tako-tsubo cardiomyopathy can also be deadly when compounded by other co-morbidities, such as heart failure, according to a study being presented March 9 at the American College of Cardiology (ACC) Scientific Sessions.

This condition, formally known as Tako-tsubo cardiomyopathy (TTC) and informally known as stress cardiomyopathy or broken heart syndrome, has abrupt onset of symptoms and is characterized by a distinctive left ventricular (LV) contraction profile. Ninety percent of the time, this condition affects women, who are usually middle aged and older, and the condition usually is triggered by a stressful event.

"Although TTC is typically reversible and considered to have favorable clinical outcomes, we have identified an important subset of patients, particularly those with severe heart failure and hypotension, who can have a substantial mortality risk," says the study's lead author Scott W. Sharkey, MD, a research cardiologist at the Minneapolis Heart Institute Foundation and a physician at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis. "It's also important that physicians are aware this is not a rare a condition, as it is present in nearly 10 percent of women who present to the hospital with suspected heart attacks."

MHIF researchers reviewed 250 TTC patients who presented to the Minneapolis Heart Institute at Abbott Northwestern Hospital between 2001 and 2012. Then, they segregated those TTC patients presenting with particularly severe heart failure and very low pressure, or hypotension (systolic blood pressure < 100 mm Hg), who required supportive treatment.

They found that severe hypotensive heart failure occurred in 45 patients. In this subset, 9 female patients died in-hospital despite aggressive treatment intervention, representing the only TTC-related hospital deaths in the 250 patient cohort.

Therefore, Sharkey and his colleagues concluded that TTC is not necessarily a benign condition. Severe hypotensive heart failure of severity necessitating vasopressor and/or intra-aortic balloon pump occurs in nearly 20 percent of patients. Also, all TTC-related hospital deaths occurred in the hypotensive heart failure subgroup with an overall mortality of 3.5 percent.

Importantly, triggering physical stressors related to severe co-morbid non-cardiac conditions (8) or advanced age (1) were present in all 9 non-survivors, Sharkey notes.

"Unfortunately, there are not any guidelines or criteria to instruct diagnosis and treatment of these patients at this time," says Sharkey. "Therefore, this study could be a starting point for this process, as it provides a more complete profile of the clinical spectrum of TTC and provides useful guidance for the effective management of these acutely ill patients."

To raise additional awareness and improve care of these patients, he adds that guidelines would be helpful at this time, in order to standardize diagnosis and treatment across varied healthcare settings.


'/>"/>

Contact: Steve Goodyear
sgoodyear@mhif.org
612-863-1658
Minneapolis Heart Institute Foundation
Source:Eurekalert

Related medicine news :

1. Newly Hired Emergency Workers Who Witness Trauma May Struggle Afterward
2. Nearly 1 in 4 women newly diagnosed with breast cancer
3. Zephanol-HP Takes Top Scores in Newly-Released Independent Diet Pill Research
4. HealthCompare Urges the Newly Increasing Numbers of 1099 Employees to Seek Health Insurance Coverage They Need
5. Newly Published Graph Discloses the Dangers and Deaths Linked with Digestive Disease
6. Newly Published by Atlantic Information Services — Dual Eligibles: The New Growth Opportunities Ahead for Health Plans
7. Newly approved oral medication slows rheumatoid arthritis joint damage
8. Neurological Wellness Center Pays Tribute to Newly Released Study Announcing TBI Treatment Breakthrough
9. Newly Updated 'Critical Bench' Teaches People How to Gain Muscle, Says Tony Nguyen
10. Newly Launched Blenderreviews101.com - The Best and Complete Resource for Blender Reviews
11. Newly Released “H Miracle” Can Teach People How to Cure Hemorrhoids, Says Health Review Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a ... Mahon was named a 2017 Top Patient Rated Henderson Dentist by Find ... that recognizes local physicians and dentists who have earned high ratings and superior patient ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
(Date:2/23/2017)... ... 23, 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior ... to the Minneapolis Home and Garden Show which is being held February 24 through ... attention is the Minneapolis Convention Center. , From its broad line of sit ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Gevir, a New ... antler velvet, announced its products are coming soon to Amazon.com, the world’s largest online ... Thomson as a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, ...
(Date:2/22/2017)... ... 22, 2017 , ... South Bend’s Lunkerville, the award-winning TV series that catches ... The Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and ... D’ traveling to Lake Denmark, New Jersey, to fish with war veteran Justin Vail ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... York , February 23, 2017 ... Holter Monitor Market are GE Healthcare, Koninklijke Philips N.V., ... about 48% in the global market in 2015. Strong ... two key factors assessed to be aiding these players ... Research states that the players in the global market ...
(Date:2/23/2017)... Mass. , Feb. 23, 2017   ... partner to global in vitro diagnostics manufacturers and ... series titled "Catalyzing Implementation of NGS-Based Tests" to ... March 30, 2017 at 11am Eastern Standard Time ... is to highlight the need for improved performance ...
(Date:2/23/2017)... MabVax Therapeutics Holdings, Inc . ... announces that it has received notice from the ... initiation a Phase I clinical trial with MVT-1075 ... ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel fully ... the phase I clinical trial in patients with ...
Breaking Medicine Technology: